Natco Pharma has launched Everolimus tablets, 1 mg, a generic version of Zortress® by Novartis, categorized as an immunosuppressant. The product will be marketed in the U.S. through Breckenridge Pharmaceutical, Inc., a subsidiary of Towa International. Everolimus is used to prevent organ rejection in adult kidney and liver transplant patients. Breckenridge previously launched Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths.
Generic Version of Zortress®
Natco Pharma has announced the launch of Everolimus tablets, 1mg, a generic version of Zortress® by Novartis. This falls under the therapeutic class of immunosuppressants.
Marketing and Distribution
Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International and Natco’s marketing partner for the ANDA, will immediately launch the product in the U.S. market.
Therapeutic Use
Everolimus is an mTOR inhibitor immunosuppressant. It is prescribed for the prophylaxis of organ rejection in adult patients who have undergone kidney and liver transplants.
Previous Launches
It’s worth noting that Breckenridge had previously launched Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths. The blister packs were launched in July 2021, followed by bottle launches in June 2023.
Source: BSE
